1215197-37-7

Basic information

• Product Name: (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid
• Synonyms: (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid;6-[[(2S)-3-Cyclopentyl-1-oxo-2-[4-(trifluoromethyl)-1H-imidazol-1-yl]propyl]amino]-3-pyridinecarboxylic acid;PF 04991532;PF-04991532
• CAS NO: 1215197-37-7
• Molecular Formula: C18H19F3N4O3
• Molecular Weight: 396.3636696
• EINECS: -0
• Mol File: 1215197-37-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 646.5±55.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.48±0.1 g/cm3(Predicted)
• Storage Temp.: room temp
• Solubility: DMSO: soluble20mg/mL, clear
• PKA: 3.55±0.10(Predicted)
• CAS DataBase Reference: (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid(1215197-37-7)
• EPA Substance Registry System: (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid(1215197-37-7)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1215197-37-7(Hazardous Substances Data)

Usage

General Description

(S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol-1-yl)propanaMido)nicotinic Acid is a chemical compound that belongs to the class of nicotinic acid derivatives. It has a molecular formula of C19H21F3N4O2 and a molecular weight of 398.39 g/mol. (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol- 1-yl)propanaMido)nicotinic Acid is a potent and selective agonist for the α7 nicotinic acetylcholine receptor (nAChR), which is a ligand-gated ion channel receptor. The α7 nAChR receptor plays a critical role in several physiological processes, including cognition, memory, and synaptic plasticity. Therefore, (S)-6-(3-Cyclopentyl-2-(4-(trifluoroMethyl)-1H-iMidazol-1-yl)propanaMido)nicotinic Acid may have potential applications in the development of new drugs for the treatment of neurological and psychiatric disorders. Additionally, it can also be used as a research tool for studying the neurobiology of nicotinic acetylcholine receptors.

Upstream product

• 1215197-36-6 (S)-benzyl 6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinate 
• 1215198-06-3 (S)-3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanoic acid 
• 1401513-92-5 C₉H₁₄O₃ 
• 33240-34-5 cyclopentylmagnesium bromide 
• 1215198-05-2 (S)-methyl 3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanoate 
• 1174013-25-2 (R)-methyl 3-cyclopentyl-2-(((trifluoromethyl)sulfonyl)oxy)-propanoate 
• 935687-49-3 benzyl 6-aminopyridine-3-carboxylate 
• 1174013-24-1 (R)-methyl 3-cyclopentyl-2-hydroxypropanoate 
• 1215198-07-4 (S)-3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanoyl chloride 
• 3167-49-5 6-aminonicotinic acid 

Relevant articles and documents

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl) propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus

Glucokinase is a key regulator of glucose homeostasis, and small molecule allosteric activators of this enzyme represent a promising opportunity for the treatment of type 2 diabetes. Systemically acting glucokinase activators (liver and pancreas) have bee

HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS

The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3, and R4 are as described herein.